Moderna will increase its deliveries to 1.33 million doses a week in July from 733,000 previously expected, raising the figure to 2.57 million a week in August and 2.95 million a week in September, the ministry said.
The FDA granted donanemab a breakthrough therapy designation, meant to expedite the development and review of medicines for serious or life-threatening conditions.
The joint announcement by AstraZeneca and Siam Bioscience, a firm owned by Thailand's king, comes amid public anxiety about vaccine supplies, as the country suffers its most severe outbreak so far.
It did not say whether the Thai plant would make all 6 million doses that Thailand's government has promised would be available this month.
"This has been driven by several factors, including significant reductions in cases in the US and other major developed countries, accelerated rollout of COVID-19 vaccines globally and, most recently, US health authority guidance on testing for fully vaccinated individuals," the drugmaker said.
Abbott sees second-quarter adjusted profit from continuing operations of at least $1 per share, compared with analysts' estimates of $1.23 per share.
Nearly 30% of the US population has been vaccinated against COVID-19, hitting demand for antibody drugs that already suffered from slower-than-expected uptake by hospitals.
Sales of other high-profile Lilly drugs also fell short of Wall Street expectations and its shares fell 3% to $181.64 in morning trading.
The Department of Health and Human Services facilitated the move, the health official said in an email, asking not to be named due to the sensitivity of the matter.
Brazil's health ministry registered a record 3,251 fatalities in 24 hours, bringing the country's overall death toll to nearly 299,000 -- second only to the United States.
Moderna's two-shot vaccine is one of the three COVID-19 vaccines authorized for emergency use in the United States along with Pfizer/BioNTech and Johnson & Johnson's.
Under the pact with Baxter, the fill and finish of Moderna COVID-19 vaccine will take place at the sterile manufacturing facilities located in Bloomington, Indiana, the companies said.
The official announcement will be made later on Friday, said the source, who requested anonymity given the sensitivity of the situation.
If the J&J vaccine has been approved, it could ease some logistical challenges. The vaccine is administered in a single dose and can be stored in normal fridges while the Pfizer-BioNTech and Moderna shots must be kept in freezers.
Takeda will be responsible for future development and commercialization of the drug, soticlestat, worldwide and Ovid will no longer have any financial obligation, the companies said.
The companies in August reported results from a mid-stage study showing soticlestat met the main goal of reduction in seizure frequency.
After scrapping development of its own COVID-19 vaccine candidates in January, Merck last month said it was working on a deal to open up its manufacturing capacity to other vaccine makers.
J&J is shipping about four million doses of its vaccine in the United States this week, but the next shipments hinge on when its new, larger manufacturing plant receives regulatory approvals.
The remarks put the United States on track to receive 240 million doses by the end of March, enough to inoculate 130 million Americans, and 700 million doses by mid-year.
Citing a Health Ministry spokeswoman, the report said the Anglo-Swedish drugmaker had offered the country further deliveries of its vaccine.
The European Commission, the European Union's executive, has signed supply deals with vaccine makers for doses to be distributed on a pro-rata basis to members states.